Genentech's flu therapy shortens time to symptom improvement by almost 30 hours in Phase III

Genentech Inc. reported additional data from the Phase III CAPSTONE-2 trial to treat influenza virus infection in patients at high risk of complications showing that baloxavir marboxil led to a median time to improvement of influenza symptoms, the primary endpoint, of 73.2 hours vs. 102.3 hours for placebo (p<0.0001). Data were presented at IDWeek in San Francisco.

The Roche (SIX:ROG; OTCQX:RHHBY) unit previously reported that baloxavir marboxil met the primary endpoint in the trial, but did not report detailed data (see "Genentech's Flu Therapy Meets in Second Phase III")...